anti-BCL2-Like 2 (BCL2L2) Anticorps

BCL2L2 encodes a member of the BCL-2 protein family. De plus, nous expédions BCL2-Like 2 Protéines (17) et BCL2-Like 2 Kits (14) et beaucoup plus de produits pour cette protéine.

afficher tous les anticorps Gène GeneID UniProt
BCL2L2 599 Q92843
BCL2L2 12050 P70345
BCL2L2 60434  
Comment commander chez anticorps-enligne
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Commandez enligne
  • orders@anticorps-enligne.fr

Top anti-BCL2-Like 2 Anticorps sur anticorps-enligne.fr

Showing 10 out of 148 products:

Catalogue No. Reactivité Hôte Conjugué Application Images Quantité Livraison Prix Détails
Boeuf (Vache) Lapin Inconjugué WB WB Suggested Anti-Bcl2l2 Antibody   Titration: 1.0 ug/ml   Positive Control: Mouse Testis 100 μL 2 to 3 Days
$289.00
Détails
Humain Lapin Inconjugué IHC (p), WB Anti- BCL2L2 antibody, IHC(P) IHC(P): Human Rectal Cancer Tissue Anti- BCL2L2 antibody,  Western blotting All lanes: Anti BCL2L2 () at 0.5ug/ml WB: HELAWhole Cell Lysate at 40ug Predicted bind size: 21KD Observed bind size: 21KD 100 μg 4 to 6 Days
$280.00
Détails
Boeuf (Vache) Lapin Inconjugué IC, IF, IHC, WB Immunofluorescent analysis of BCLW staining in HL60 cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 °C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark. DAPI was used to stain the cell nuclei (blue). Immunohistochemical analysis of BCLW staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX. 200 μL 13 to 14 Days
$487.50
Détails
Humain Lapin Inconjugué IF, ELISA, WB Western blot analysis of extracts from COLO cells, using BCLW Antibody. The lane on the right is treated with the synthesized peptide. Immunofluorescence analysis of HepG2 cells, using BCLW Antibody. The picture on the right is treated with the synthesized peptide. 100 μg 2 to 3 Days
$302.50
Détails
Humain Lapin Inconjugué ELISA, IF, IHC, WB 100 μL Disponible
$363.46
Détails
Humain Lapin Inconjugué ELISA, ICC, IF, IHC, WB Western blot analysis of HL-60  lysate using BCL2L2 antibody. The lane on the left is treated with the antigen-specific peptide. ABIN6276561 staining COLO205 cells by IF/ICC. The sample were fixed with PFA and permeabilized in 0.1% Triton X-100,then blocked in 10% serum for 45 minutes at 25¡ãC. The primary antibody was diluted at 1/200 and incubated with the sample for 1 hour at 37¡ãC. An  Alexa Fluor 594 conjugated goat anti-rabbit IgG (H+L) antibody(Cat.# S0006), diluted at 1/600, was used as secondary antibod 100 μL 11 to 12 Days
$390.77
Détails
Humain Lapin Inconjugué ELISA, ICC, IF, WB Western blot analysis of extracts from COLO cells, using BCLW antibody. ABIN6274678 staining COLO205 cells by IF/ICC. The sample were fixed with PFA and permeabilized in 0.1% Triton X-100,then blocked in 10% serum for 45 minutes at 25°C. The primary antibody was diluted at 1/200 and incubated with the sample for 1 hour at 37°C. An Alexa Fluor 594 conjugated goat anti-rabbit IgG (H+L) antibody(Cat.# S0006), diluted at 1/600, was used as secondary antibody. 100 μL 11 to 12 Days
$390.77
Détails
Humain Souris Inconjugué ELISA, FACS, WB Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng) Western blot analysis using BCL2L2 mAb against human BCL2L2 (AA: 6-118) recombinant protein. (Expected MW is 38.2 kDa) 0.1 mg 3 to 4 Days
$430.10
Détails
Humain Souris Inconjugué ELISA, FACS, ICC, IHC, WB Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng) Western blot analysis using BCL2L2 mAb against human BCL2L2 (AA: 6-118) recombinant protein. (Expected MW is 38.2 kDa) 0.1 mg 3 to 4 Days
$430.10
Détails
Humain Lapin Inconjugué IHC, WB 100 μL 11 to 13 Days
$366.77
Détails

Plus d’anticorps contre BCL2-Like 2 partenaires d’interaction

Human BCL2-Like 2 (BCL2L2) interaction partners

  1. HOTAIR up-regulates Bcl-w to enhance cell proliferation through sequestering miR-206 in breast cancer

  2. Data found that Bcl-w promotes epithelial-mesenchymal transition by increasing respiratory complex-I activity and reactive oxygen species (ROS) levels.

  3. the present study demonstrates that miR-422a may serve as a tumor suppressor in osteosarcoma via inhibiting BCL2L2 and KRAS translation both in vitro and in vivo Therefore, miR-422a could be developed as a novel therapeutic target in osteosarcoma.

  4. BCL2L2 knockdown was attenuated the effects of SNHG1 overexpression on cell viability, cell apoptosis and protein levels of cleaved caspase-3, cleaved caspase-9 and Bax in H2O2-treated human cardiomyocytes.

  5. Our comprehensive analysis indicates B-cell lymphomas commonly select for BCLW overexpression in combination with or instead of other antiapoptotic BCL2 family members.

  6. BCL-W contributes to the threshold of anti-apoptotic activity during mitosis

  7. we demonstrated that miR-126-5p plays an inhibitory role in human cervical cancer progression, regulating the apoptosis of cancer cells via directly targeting Bcl2l2.

  8. High expression of Bcl-w was associated with mesenchymal changes and invading populations in the glioblastoma multiforme; Bcl-w functions as a positive regulator of invasion by enhancing mesenchymal traits of glioblastoma multiforme, consequently contributing to malignancy.

  9. BCL2L2 was the virtual target of miR-133b, and we found a negative regulatory relationship between miR-133b and BCL2L2. MiR-133b and BCL2L2 interfered with the viability and apoptosis of cells.

  10. overexpression of miR-15a in the FaDu cells was associated with significantly decreased BCL2L2 and BCL2 expression and a significant increase in the apoptosis rate. The opposite results were observed in HPV-positive HSCC, where downregulation of miR-15a suppressed apoptosis

  11. we conclude that BER treatment reduces cisplatin resistance of gastric cancer cells by modulating the miR-203/Bcl-w apoptotic axis. BER may be a novel agent to enhance chemotherapeutic responses in cisplatin-resistant gastric cancer patients

  12. Genetic and pharmacological inhibition of BCL-W and BCL-XL causes directed elimination of senescent cells.

  13. Data show that BCL2-like 2 protein (BCL2L2) is a direct target of micrRNA miR-29b.

  14. these results indicate that miR-335 acts as a novel tumor suppressor to regulate ccRCC cell proliferation and invasion through downregulation of BCL-W expression.

  15. miR-15a acts as a tumor suppressor in NSCLC by directly targeting BCL2L2 and may serve as a potential diagnostic biomarker and therapeutic target for NSCLC.

  16. The crystal structures of BCL-W and BCL-XL, along with cellular, studies reveal critical features of the BH3 domains of pro-survival proteins that distinguish them functionally from their pro-apoptotic counterparts.

  17. over-expression of miR-195 sensitized resistant cells to DOX and enhanced cell apoptosis activity, all of which can be partly rescued by BCL2L2 siRNA and cDNA expression

  18. A structural basis for a conserved binding mechanism between p53DBD and the anti-apoptotic Bcl-2 family proteins.

  19. Bcl-w-induced Sp1 activation is a potential marker for aggressiveness of glioblastoma multiforme.

  20. HDMF inhibits Bcl-w-induced neurosphere formation and the expression of glioma stem cell markers, such as Musashi, Sox-2 and c-myc.

Mouse (Murine) BCL2-Like 2 (BCL2L2) interaction partners

  1. MYC regulates BCL-W expression through its transcriptional regulation of specific miR.

  2. Genetic and pharmacological inhibition of BCL-W and BCL-XL causes directed elimination of senescent cells.

  3. NF-kappaB p65/p52 signaling mediated the effects of GDNF on Bcl-2 and Bcl-w expressions

  4. Target-derived neurotrophins coordinate transcription of the antiapoptotic gene bclw with transport of bclw mRNA to the axon, and thereby prevent axonal degeneration in rat and mouse sensory neurons.

  5. By using human cancer cells and mouse embryonic fibroblasts, the study shows that Bcl-w functions in the mitochondria to increase the levels of reactive oxygen species (ROS), which subsequently stimulates the invasion-promoting signaling pathway.

  6. Bcl-2, Bcl-x(L) and Bcl-w have only minor roles in thymic lymphoma development elicited by defects in p53, and this may indicate that Mcl-1 and/or A1 may feature more prominently in this process.

  7. Induction of autocrine Bcl-w signaling through pericytes promoting endothelial cell survival is associated with melanoma development.

  8. Bcl-w(-/-) sensory neurons exhibit mitochondrial abnormalities, including alterations in axonal mitochondrial size, axonal mitochondrial membrane potential, and cellular ATP levels.

  9. Bcl-x(L) and Bcl-w target protein phosphatase 1alpha to Bad

  10. Bcl-2, Bcl-w, and Bax act in a redundant manner in regulating granulocyte survival and death

  11. amino acid and base sequences of c98 gene (bcl-2 homolog) expressed in newborn epidermal keratinocytes treated with IGF-1

  12. The crypt expression of Bax and Bcl-w is influenced by epidermal growth factor receptor signaling and is key for the regulation of apoptosis.

  13. These data identify Bcl-w as an endogenous neuroprotectant that may have seizure-suppressive functions.

  14. Bcl-w and Grid2 act in distinct pathways to regulate mitochondrial morphogenesis and control Purkinje cell dendrite development and synapse formation.

Cow (Bovine) BCL2-Like 2 (BCL2L2) interaction partners

  1. Chromosome mapping of BCL2L2 gene in cows.

BCL2-Like 2 (BCL2L2) profil antigène

Profil protéine

This gene encodes a member of the BCL-2 protein family. The proteins of this family form hetero- or homodimers and act as anti- and pro-apoptotic regulators. Expression of this gene in cells has been shown to contribute to reduced cell apoptosis under cytotoxic conditions. Studies of the related gene in mice indicated a role in the survival of NGF- and BDNF-dependent neurons. Mutation and knockout studies of the mouse gene demonstrated an essential role in adult spermatogenesis. Alternative splicing results in multiple transcript variants. Read-through transcription also exists between this gene and the neighboring downstream PABPN1 (poly(A) binding protein, nuclear 1) gene.

Gene names and symbols associated with anti-BCL2-Like 2 (BCL2L2) Anticorps

  • BCL2-like 2 (bcl2l2) anticorps
  • BCL2 like 2 (BCL2L2) anticorps
  • BCL2-like 2 (Bcl2l2) anticorps
  • Bcl2-like 2 (Bcl2l2) anticorps
  • AW048834 anticorps
  • Bcl-w anticorps
  • BCL-WEL anticorps
  • BCL-WS anticorps
  • BCL2-L-2 anticorps
  • BCL2L2 anticorps
  • Bclw anticorps
  • c98 anticorps
  • Gtrgal2 anticorps
  • Gtrosa41 anticorps
  • PPP1R51 anticorps

Protein level used designations for anti-BCL2-Like 2 (BCL2L2) Anticorps

Bcl2-like 2 , BCL2-like 2 , apoptosis regulator BCL-W , bcl-2-like protein 2 , protein phosphatase 1, regulatory subunit 51 , apoptosis regulator Bcl-W , bcl2-L-2

GENE ID SPECIES
496475 Xenopus (Silurana) tropicalis
768265 Felis catus
599 Homo sapiens
12050 Mus musculus
490611 Canis lupus familiaris
60434 Rattus norvegicus
767601 Bos taurus
Fournisseurs de qualité sélectionnés pour anti-BCL2-Like 2 (BCL2L2) Anticorps
Avez-vous cherché autre chose?